Madeline Ruzicka
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Madeline Ruzicka has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Adegoke Adeniji
South University School of Pharmacy, South University, 709 Mall Blvd., Savannah, GA 31406, USA
1 shared publication - Ayodeji A. Agbowuro
South University School of Pharmacy, South University, 709 Mall Blvd., Savannah, GA 31406, USA
1 shared publication - Christopher Brackett
South University School of Pharmacy, South University, 709 Mall Blvd., Savannah, GA 31406, USA
1 shared publication - Daya Gupta
South University School of Pharmacy, South University, 709 Mall Blvd., Savannah, GA 31406, USA
1 shared publication - Onyinyechi Emeri
South University School of Pharmacy, South University, 709 Mall Blvd., Savannah, GA 31406, USA
1 shared publication - Stan Heath
South University School of Pharmacy, South University, 709 Mall Blvd., Savannah, GA 31406, USA
1 shared publication
Latest Publications
- Open Access
- 26 July 2026
- Published by MDPI AG in Brain Sciences
- Vol. 16 (8) , 786
The Role of the NMDA Receptor in the Treatment of Psychiatric and Neurological Diseases
The N-methyl-D-aspartate receptor (NMDAR) is an ionotropic glutamate receptor widely expressed in the CNS and in peripheral tissues where it mediates crucial physiological functions and its dysregulation has been linked to a host of neurological and psychiatric disorders including Alzheimer’s disease, schizophrenia, epilepsy, and chronic pain. This work highlights the therapeutic potential in targeting the NMDAR in these disease states by providing a holistic analysis of the existing literature focused on the molecular role of the receptor in applicable disease conditions. While several drugs targeting the NMDAR have been approved for clinical use, many more are in clinical and preclinical development. A significant part of this review assesses the chemical and pharmacological attributes of these molecules and provides a prognostic perspective for their use.
- 26 July 2026
- Published by MDPI AG in Brain Sciences
- Vol. 16 (8) , 786
Open AccessThe Role of the NMDA Receptor in the Treatment of Psychiatric and Neurological Diseases
The N-methyl-D-aspartate receptor (NMDAR) is an ionotropic glutamate receptor widely expressed in the CNS and in peripheral tissues where it mediates crucial physiological functions and its dysregulation has been linked to a host of neurological and psychiatric disorders including Alzheimer’s disease, schizophrenia, epilepsy, and chronic pain. This work highlights the therapeutic potential in targeting the NMDAR in these disease states by providing a holistic analysis of the existing literature focused on the molecular role of the receptor in applicable disease conditions. While several drugs targeting the NMDAR have been approved for clinical use, many more are in clinical and preclinical development. A significant part of this review assesses the chemical and pharmacological attributes of these molecules and provides a prognostic perspective for their use.